The estimated Net Worth of Allan M. Fox is at least $25.8 million dollars as of 22 December 2021. Mr. Fox owns over 112,869 units of Regenxbio Inc stock worth over $19,446,059 and over the last 9 years he sold RGNX stock worth over $6,087,840. In addition, he makes $309,316 as Chairman of the Board at Regenxbio Inc.
Allan has made over 2 trades of the Regenxbio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 112,869 units of RGNX stock worth $3,915,426 on 22 December 2021.
The largest trade he's ever made was selling 112,869 units of Regenxbio Inc stock on 22 December 2021 worth over $3,915,426. On average, Allan trades about 10,740 units every 6 days since 2015. As of 22 December 2021 he still owns at least 1,529,981 units of Regenxbio Inc stock.
You can see the complete history of Mr. Fox stock trades at the bottom of the page.
Allan M. Fox J.D. serves as Chairman of the Board of the Company. He has been a Director since February 2009. Mr. Fox is the founding partner of FOXKISER LLP (“FOXKISER”), a firm committed to the strategic development of transformative innovations from biomedical research, which was formed in September 1986. Mr. Fox specializes in identifying business opportunities and improving competitive market positions. Through FOXKISER, he has participated in the formation and development of numerous ventures in the public and private sectors, including the founding of REGENXBIO and Dimension Therapeutics, Inc. Before forming FOXKISER, Mr. Fox co-led the establishment of the Washington office of the law firm of Kaye Scholer. While in the public sector, Mr. Fox served as Chief of Staff and Chief Legislative Assistant to U.S. Senator Jacob K. Javits of New York. He also served as Chief Counsel to the United States Senate Health and Scientific Research Subcommittee, chaired by Senator Edward M. Kennedy. Mr. Fox has served as a director at WindMIL Therapeutics, Inc., a privately held biotechnology company, since March 2017. Mr. Fox was a Fellow in Law, Science and Medicine at Yale Law School where he received an LL.M. degree. Mr. Fox also holds a J.D. and B.A. from Temple University. Mr. Fox has specific attributes that qualify him to continue to serve as a member of the Board, including his broad experience in providing strategic advice to and investing in biotechnology companies throughout their life cycles, his expertise in identifying business opportunities, his deep experience with REGENXBIO since the time of its founding and his current and prior service on boards of directors.
As the Chairman of the Board of Regenxbio Inc, the total compensation of Allan Fox at Regenxbio Inc is $309,316. There are 18 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
Allan Fox is 72, he's been the Chairman of the Board of Regenxbio Inc since 2020. There are no older and 19 younger executives at Regenxbio Inc.
Allan's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas et Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Regenxbio Inc executives and other stock owners filed with the SEC include: